EUVIMEDEUVIMED entdecken
CrossrefInfokarte

HPV16/18 Genotype and Histologic High-Grade Disease in Women with ASC-H Cytology: A Systematic Review of Genotype-Stratified Outcomes

Maria-Daniela Vasieș (Mazilu), Elena-Lavinia Rusu, Jasmina-Sorina Chiriac, Alexandra-Corina Faur, Elena-Rodica Heredea, Veronica-Daniela Chiriac

Diagnostics · 2026-11-11 · 16 (22) · 3727

DOI: 10.3390/diagnostics16223727 ↗
AbstractBibliografische Angaben

Abstract

Background/Objectives: Human papillomavirus (HPV) genotyping may stratify histologic risk among women with atypical squamous cells that cannot exclude high-grade squamous intraepithelial lesion (ASC-H). We evaluated genotype-specific high-grade outcomes. Methods: PubMed and Europe PMC were searched on 1 October 2026 and updated on 7 October 2026. Two reviewers independently screened, extracted, and appraised studies in accordance with PRISMA 2020. Eligible English language studies provided ASC-H-specific histologic outcomes for HPV16/18-defined and comparator groups. Risk of bias was appraised with an adapted QUADAS-2 framework (the protocol-specified Joanna Briggs Institute prevalence checklist is reported in an appendix), and certainty was rated with GRADE. An exploratory restricted meta-analysis compared HPV16/18 with other high-risk HPV (hrHPV) for CIN2+/HSIL+ using random effects and modified Hartung–Knapp confidence intervals. Results: Sixteen studies in 17 reports were included; six contributed 1655 women to the restricted comparison. The pooled risk ratio was 1.19 (95% confidence interval, 0.94–1.49), with substantial heterogeneity (I2 = 64.9%) and a prediction interval of 0.70–2.01. The results varied with study selection and genotype definition. In four studies with at least 30 hrHPV-negative women, high-grade outcomes occurred in 6.8–18.4%, and HPV-negative carcinomas were reported. Leave-one-out, screening context, and verification-restricted analyses did not show a consistent difference (histology in all participants: RR 1.01, 0.63–1.62). Incomplete verification, confounding by age and screening context, heterogeneous assays and populations, and inaccessible reports limited confidence; certainty was very low for both outcomes. Conclusions: A modest relative difference between HPV16/18 and other hrHPV types cannot be excluded, but the pooled evidence does not demonstrate a consistent incremental risk difference. Other hrHPV types and negative hrHPV results do not exclude high-grade disease. These findings are consistent with current guidance for colposcopic evaluation of all ASC-H without genotype-based deferral.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →